Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 17-44

  Smallridge, Robert C ^a   Marlow, Laura A ^a   Copland, John A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; APC PROTEIN; B RAF KINASE; BETA1 CATENIN; CATENIN; CETUXIMAB; COMBRETASTATIN A4 PHOSPHATE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DEHYDROXYMETHYLEPOXYQUINOMICIN; DOXORUBICIN; GEFITINIB; GEMCITABINE; IMATINIB; MANUMYCIN; MEVINOLIN; MICRORNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ONYX 015; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLERIXAFOR; PROTEIN P53; PROTEIN RET; RAF PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; WNT PROTEIN;

ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; EPIGENETICS; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE MUTATION; HUMAN; LOW DRUG DOSE; MEDLINE; MICROARRAY ANALYSIS; MITOSIS; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROIDECTOMY; TUMOR DIFFERENTIATION; ANIMAL; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; THYROID TUMOR;

ANIMALS; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; THYROID NEOPLASMS;

EID: 65549128212     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0154     Document Type: Review

References (227)

1. Abbosh PH, Li X, Li L, Gardner TA & Nephew KP 2007 KPA conditionally replicative, Wnt/β-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Therapy 14 399-408.
2. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A 2006 APeroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147 4463-4475.
3. Ain KB, Tofiq S & Taylor K 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. Journal of Clinical Endocrinology and Metabolism 81 3650-3653.
4. Ain KB, Egorin MJ & DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion, Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 10 587-594.
5. Akaishi J, Onda M, Okamoto J, Miyamoto S, Nagahama M, Ito K, Yoshida A & Shimizu K 2006 Down-regulation of transcription elongation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer. BMC Cancer 6 260.
6. Altieri DC 2008 Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews. Cancer 8 61-70.
7. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Marchetti I, Ugolini C, Basolo F, Miccoli P & Ferrannini E 2008 Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. European Journal of Endocrinology 159 283-291.
8. Appels NM, Beijnen JH & Schellens JH 2005 Development of farnesyl transferase inhibitors: a review. Oncologist 10 565-578.
9. Arlot-Bonnemains Y, Baldini E, Martin B, Delcros JG, Toller M, Curcio F, Ambesi-Impiombato FS, d'Armiento M & Ulisse S 2008 Effects of the aurora kinases inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocrine-Related Cancer 15 559-568.
10. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, Barone MV, Chiappetta G, Vento MT, Spiezia S et al. 1999 Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. Journal of Clinical Investigation 104 865-874.
11. Balthasar S, Bergelin N, Lof C, Vainio M, Andersson S & Tornquist K 2008 Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells. Endocrine-Related Cancer 15 521-534.
12. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D & Westra WH 2004 BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology 17 1359-1363.
13. Bejarano PA, Nikiforov YE, Swenson ES & Biddinger PW 2000 Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Applied Immunohistochemistry and Molecular Morphology 8 189-194.
14. Bejjani BA & Shaffer LG 2006 Application of array-based comparative genomic hybridization to clinical diagnostics. Journal of Molecular Diagnostics 8 528-533.
15. Berlingieri MT, Pierantoni GM, Giancotti V, Santoro M & Fusco A 2002 Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 21 2971-2980.
16. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S & Vodnik A 2001 Effect of primary treatment on survival in anaplastic thyroid carcinoma. European Journal of Surgical Oncology 27 260-264.
17. Besic N, Hocevar M, Zgajnar J, Pogacnik A, Grazio-Frkovic S & Auersperg M 2005 Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients. Langenbeck's Archives of Surgery 390 203-208.
18. Bhat KM & Setaluri V 2007 Microtubule-associated proteins as targets in cancer chemotherapy. Clinical Cancer Research 13 2849-2854.
19. Bishop SC, Burlison JA & Blagg BS 2007 Hsp90: a novel target for the disruption of multiple signaling cascades. Current Cancer Drug Targets 7 369-388.
20. Blagosklonny MV, Giannakakou P, Wojtowicz M, Romanova LY, Ain KB, Bates SE & Fojo T 1998 Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 83 2516-2522.
21. Blansfield JA, Caragacianu D, Alexander HR 3rd, Tangrea MA, Morita SY, Lorang D, Schafer P, Muller G, Stirling D, Royal RE et al. 2008 Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clinical Cancer Research 14 270-280.
22. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM et al. 2008 MicroRNAs modulate the chemosensitivity of tumor cells. Molecular Cancer Therapeutics 7 1-9.
23. Boltze C, Roessner A, Landt O, Szibor R, Peters B & Schneider-Stock R 2002 Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. International Journal of Oncology 21 1151-1154.
24. Bonofiglio D, Qi H, Gabriele S, Catalano S, Aquila S, Belmonte M & Ando S 2008 Peroxisome proliferator-activated receptor γ inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocrine-Related Cancer 15 545-557.
25. Bravo SB, Garcia-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, Lopez-Lazaro L, Zalvide J, Barreiro F, Pombo CM & Alvarez CV 2005 Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clinical Cancer Research 11 7664-7673.
26. Brignardello E, Gallo M, Baldi I, Palestini N, Piovesan A, Grossi E, Ciccone G & Boccuzzi G 2007 Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. European Journal of Endocrinology 156 425-430.
27. Bulgin D, Podtcheko A, Takakura S, Mitsutake N, Namba H, Saenko V, Ohtsuru A, Rogounovitch T, Palona I & Yamashita S 2006 Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest. Thyroid 16 217-224.
28. Calin GA & Croce CM 2006 MicroRNA signatures in human cancers. Nature Reviews. Cancer 6 857-866.
29. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M et al. 2004 Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. PNAS 101 2999-3004.
30. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M & Boccuzzi G 2006 Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. Journal of Endocrinology 191 465-472.
31. Catalano MG, Poli R, Pugliese M, Fortunati N & Boccuzzi G 2007 Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocrine-Related Cancer 14 839-845.
32. Chan JA, Krichevsky AM & Kosik KS 2005 MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Research 65 6029-6033.
33. Chemotherapy Committee. The Japanese Society of Thyroid Surgery 1995 Intensive chemotherapy for anaplastic thyroid carcinoma: combination of cisplatin, doxorubicin, etoposide and peplomycin with granulocyte colony-stimulating factor support. Japanese Journal of Clinical Oncology 25 203-207.
34. Chiappetta G, Tallini G, De Biasio MC, Pentimalli F, de Nigris F, Losito S, Fedele M, Battista S, Verde P, Santoro M et al. 2000 FRA-1 expression in hyperplastic and neoplastic thyroid diseases. Clinical Cancer Research 6 4300-4306.
35. Cho K, Wang X, Nie S, Chen ZG & Shin DM 2008 Therapeutic nanoparticles for drug delivery in cancer. Clinical Cancer Research 14 1310-1316.
36. Ciardiello F & Tortora G 2008 EGFR antagonists in cancer treatment. New England Journal of Medicine 358 1160-1174.
37. Climent J, Garcia JL, Mao JH, Arsuaga J & Perez-Losada J 2007 Characterization of breast cancer by array comparative genomic hybridization. Biochemistry and Cell Biology 85 497-508.
38. Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P et al. 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal Clinical Oncology 26 4708-4713.
39. Conticello C, Adamo L, Giuffrida R, Vicari L, Zeuner A, Eramo A, Anastasi G, Memeo L, Giuffrida D, Iannolo G et al. 2007 Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. Journal of Clinical Endocrinology and Metabolism 92 1938-1942.
40. Copland JA, Marlow LA, Gumz M, Kreinest PA, Kurakata S, Fujiwara K, McIver B, Sebo T & Smallridge RC 2006a Peroxisome proliferator activated receptor gamma (PPARγ) transcriptionally regulates RhoB, a tumor suppressor essential for PPARγ mediated antitumor activity in anaplastic thyroid carcinoma (ATC). Annual Meeting of the American Thyroid Association, Phoenix, AZ, Oct 14. Abstract.
41. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC 2006b Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25 2304-2317.
42. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J & Garcia-Rostan G 2008 BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clinical Endocrinology 68 618-634.
43. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B & Schlumberger M 2004 Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. International Journal of Radiation Oncology, Biology, Physics 60 1137-1143.
44. Croce CM 2008 Oncogenes and cancer. New England Journal of Medicine 358 502-511.
45. Dahlman T, Grimelius L, Wallin G, Rubin K & Westermark K 1998 Integrins in thyroid tissue: upregulation of α2β1 in anaplastic thyroid carcinoma. European Journal of Endocrinology 138 104-112.
46. Done SJ 2006 Diagnostic array comparative genomic hybridization: is it ready for prime time? Journal of Molecular Diagnostics 8 527.
47. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 91 1753-1760.
48. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B et al. 2002 A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Research 62 3408-3416.
49. Dziba JM & Ain KB 2004 Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro. Journal of Clinical Endocrinology and Metabolism 89 2127-2135.
50. Dziba JM, Marcinek R, Venkataraman G, Robinson JA & Ain KB 2002 Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12 1063-1070.
51. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, Clayman GL & El-Naggar AK 2008 Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Human Pathology 39 15-20.
52. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, Mikuz G & Schmid KW 2004 Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Annals of the New York Academy of Sciences 1030 69-77.
53. Esquela-Kerscher A & Slack FJ 2006 Oncomirs - micro-RNAs with a role in cancer. Nature Reviews. Cancer 6 259-269.
54. Esteller M 2008 Epigenetics in cancer. New England Journal of Medicine 358 1148-1159.
55. Eszlinger M, Krohn K, Kukulska A, Jarzab B & Paschke R 2007 Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocrine Reviews 28 322-338.
56. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184.
57. De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M & Melillo RM 2007 Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Research 67 11821-11829.
58. Ferreira CG, Epping M, Kruyt FA & Giaccone G 2002 Apoptosis: target of cancer therapy. Clinical Cancer Research 8 2024-2034.
59. Finley DJ, Arora N, Zhu B & Fahey TJ 3rd 2004 Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. Journal of Clinical Endocrinology and Metabolism 89 3214-3223.
60. Franzen A & Heldin NE 2001 BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Biochemical and Biophysical Research Communications 285 773-781.
61. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S et al. 2004 Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 23 7436-7440.
62. Frohling S & Dohner H 2008 Chromosomal abnormalities in cancer. New England Journal of Medicine 359 722-734.
63. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 6455-6457.
64. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG et al. 2007 A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 59 467-475.
65. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML & Rimm DL 1999 Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Research 59 1811-1815.
66. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL & Tallini G 2001 Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. American Journal of Pathology 158 987-996.
67. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J & Tallini G 2003 Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 21 3226-3235.
68. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J & Santoro M 2005 Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Research 65 10199-10207.
69. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr & Gandara DR 2008 Aurora kinases as anticancer drug targets. Clinical Cancer Research 14 1639-1648.
70. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K et al. 2005 Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 6646-6656.
71. Griffith OL, Melck A, Jones SJ & Wiseman SM 2006 Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. Journal of Clinical Oncology 24 5043-5051.
72. Gunn SR, Robetorye RS & Mohammed MS 2007 Comparative genomic hybridization arrays in clinical pathology: progress and challenges. Molecular Diagnosis & Therapy 11 73-77.
73. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY & Clark OH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91 2335-2342.
74. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T, Amino N, Sakon M & Monden M 2004 Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. International Journal of Oncology 24 89-95.
75. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S et al. 2005 The role of microRNA genes in papillary thyroid carcinoma. PNAS 102 19075-19080.
76. Hemmer S, Wasenius VM, Knuutila S, Franssila K & Joensuu H 1999 DNA copy number changes in thyroid carcinoma. American Journal of Pathology 154 1539-1547.
77. Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, Hofbauer LC, Rothmund M & Zielke A 2007 Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 31 105-113.
78. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170.
79. Hou P, Ji M & Xing M 2008 Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113 2440-2447.
80. Husmark J, Heldin NE & Nilsson M 1999 N-cadherin-mediated adhesion and aberrant catenin expression in anaplastic thyroid-carcinoma cell lines. International Journal of Cancer 83 692-699.
81. Iannetti A, Pacifico F, Acquaviva R, Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A, Vuttariello E et al. 2008 The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. PNAS 105 14058-14063.
82. Inazawa J, Inoue J & Imoto I 2004 Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Science 95 559-563.
83. Ito Y, Yoshida H, Uruno T, Nakano K, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kakudo K et al. 2003a Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncology Reports 10 1337-1340.
84. Ito Y, Yoshida H, Shibahara K, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F et al. 2003b Y-box binding protein expression in thyroid neoplasms: its linkage with anaplastic transformation. Pathology International 53 429-433.
85. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T & Thun MJ 2008 Cancer statistics. CA: A Cancer Journal for Clinicians 58 71-96.
86. Jenkins RB, Hay ID, Herath JF, Schultz CG, Spurbeck JL, Grant CS, Goellner JR & Dewald GW 1990 Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer 66 1213-1220.
87. Jeyaseelan K, Herath WB & Armugam A 2007 MicroRNAs as therapeutic targets in human diseases. Expert Opinion on Therapeutic Targets 11 1119-1129.
88. Junor EJ, Paul J & Reed NS 1992 Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. European Journal of Surgical Oncology 18 83-88.
89. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC & Cheng SY 2006 PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene 25 2736-2747.
90. Kebebew E, Peng M, Treseler PA, Clark OH, Duh QY, Ginzinger D & Miner R 2004 Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 89 6105-6111.
91. Kebebew E, Greenspan FS, Clark OH, Woeber KA & McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 1330-1335.
92. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J & Hoang-Vu C 2004 Expression, regulation and function of autotaxin in thyroid carcinomas. International Journal of Cancer 109 833-838.
93. Kerbel RS 2008 Tumor angiogenesis. New England Journal of Medicine 358 2039-2049.
94. Kim JH & Leeper RD 1983 Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adrimnycin and radiation therapy. A new approach. Cancer 52 954-957.
95. Kim SJ, Park JW, Yoon JS, Mok JO, Kim YJ, Park HK, Kim CH, Byun DW, Lee YJ, Jin SY et al. 2004 Increased expression of focal adhesion kinase in thyroid cancer: inmumohistochemical study. Journal of Korean Medical Science 19 710-715.
96. Kim S, Schiff BA, Yigitbasi OG, Doan D, Jasser SA, Bekele BN, Mandal M & Myers JN 2005a Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Molecular Cancer Therapeutics 4 632-640.
97. Kim S, Park YW, Schiff BA, Doan DD, Yazici Y, Jasser SA, Younes M, Mandal M, Bekele BN & Myers JN 2005b An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clinical Cancer Research 11 1713-1721.
98. Kitamura Y, Shimizu K, Tanaka S, Ito K & Emi M 2000 Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q. Genes, Chromosomes and Cancer 27 244-251.
99. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S & Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/ I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 86 3430-3435.
100. Kitazono M, Chuman Y, Aikou T & Fojo T 2002 Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathway. International Journal of Cancer 99 453-459.
101. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F & Monden M 1996 Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head & Neck 18 36-41.
102. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM & Fletcher JA 2000 PAX8-PPARgammal fusion oncogene in human thyroid carcinoma (corrected). Science 289 1357-1360.
103. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T & Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemotherapy and Pharmacology 58 460-470.
104. Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata. Y, Ozaki S, Okajima M, Sugino K & Asahara T 2004 Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid 14 1020-1029.
105. Lam KY, Lo CY, Chan KW & Wan KY 2000 Insular and anaplastic carcinoma of the thyroid: a 45-year, comparative study at a single institution and a review of the significance of p53 and p21. Annals of Surgery 231 329-338.
106. Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA & Fagin JA 2008 BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. Journal of Clinical Endocrinology and Metabolism 93 2194-2201.
107. Lee JJ, Foukakis T, Hashemi J, Grimelius L, Heldin NE, Wallin G, Rudduck C, Lui WO, Hoog A & Larsson C 2007 Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid 17 289-301.
108. Lee JJ, Au AY, Foukakis T, Barbaro M, Kiss N, CliftonBligh R, Staaf J, Borg A, Delbridge L, Robinson BG et al. 2008 Array-CGH identifies cyclin DI and UBCHIO amplicons in anaplastic thyroid carcinoma. EndocrineRelated Cancer 15 801-815.
109. Levendag PC, De Porre PM & van Putten WL 1993 Anaplastic carcinoma of the thyroid gland treated by radiation therapy. International Journal of Radiation, Oncology, Biology, Physics 26 125-128.
110. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A & Portella G 2007 Lovastatin enhances the replication of the oncolytic adenovirus d11520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 148 5186-5194.
111. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA, Timiryasova T, Chen N, Shah JP, Szalay AA et al. 2007 Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 142 976-983.
112. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L, Zhang Q, Yu YA, Chen N, Szalay AA et al. 2008 Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. Journal of Clinical Endocrinology and Metabolism 93 4403-4407.
113. Liu D & Ying M 2008 Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the P13K and NF-kappaB pathways. Thyroid 18 853-864.
114. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK & Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 3106-3116.
115. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA et al. 2005 MicroRNA expression profiles classify human cancers. Nature 435 834-838.
116. Malaguarnera R, Vella V, Vigneri R & Frasca F 2007 p53 family proteins in thyroid cancer. Endocrine-Related Cancer 14 43-60.
117. Mark J, Ekedahl C, Dahlenfors R & Westermark B 1987 Cytogenetical observations in five human anaplastic thyroid carcinomas. Hereditas 107 163-174.
118. Mazzanti C, Zeiger MA, Costourous N, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR & Libutti SK 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Research 64 2898-2903.
119. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, van Heerden JA & Goellner JR 2001 Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 130 1028-1034.
120. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M et al. 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation 115 1068-1081.
121. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD & Patel T 2006 Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma. cell lines. Gastroenterology 130 2113-2129.
122. Meng Z, Mitsutake N, Nakashima M, Starenki D, Matsuse M, Takakura S, Namba H, Saenko V, Umezawa K, Ohtsuru A et al. 2008 DHMEQ, a novel NF-κB inhibitor, enhances anti-tumor activity of taxanes in anaplastic thyroid cancer cells. Endocrinology 149 5357-5365.
123. Miettinen M & Franssila KO 2000 Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Human Pathology 31 1139-1145.
124. Mineva I, Gartner W, Hauser P, Kainz A, Loffler M, Wolf G, Oberbauer R, Weissel M & Wagner L 2005 Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaBcrystallin gene (CRYAB) silencing. Cell Stress and Chaperones 10 171-184.
125. Mitchell G, Huddart R & Harmer C 1999 Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiotherapy and Oncology 50 33-38.
126. Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N et al. 2008 Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Science 99 280-286.
127. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB & Mitsiades N 2006 Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Journal of Clinical Endocrinology and Metabolism 91 4013-4021.
128. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, TseleniBalafouta S, Poulaki V, Batt D et al. 2007 Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Molecular Cancer Therapeutics 6 1070-1078.
129. Miura D, Wada N, Chin K, Magrane GG, Wong M, Duh QY & Clark OH 2003 Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization. Thyroid 13 283-290.
130. Miyake N, Maeta H, Horie S, Kitamura Y, Nanba E, Kobayashi K & Terada T 2001 Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas. Pathology International 51 680-685.
131. Mizutani K, Onda M, Asaka S, Akaishi J, Miyamoto S, Yoshida A, Nagahama M, Ito K & Emi M 2005 Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. Cancer 103 1785-1790.
132. Montero-Conde C, Martin-Campos JM, Lerma E, Gimenez G, Martinez-Guitarte JL, Combalia N, Montaner D, MatiasGuiu X, Dopazo J, de Leiva A et al. 2008 Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene 27 1554-1561.
133. Motti ML, Califano D, Baldassarre G, Celetti A, Merolla F, Forzati F, Napolitano M, Tavemise B, Fusco A & Viglietto G 2005 Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis 26 1021-1034.
134. Nagayama Y, Nishibara E, Namba H, Yokoi H, Hasegawa M, Mizuguchi H, Hayakawa T, Hamada H, Yamashita S & Niwa M 2001 Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/IoxP system. Cancer Gene Therapy 8 36-44.
135. Nakashima M, Takamura N, Namba H, Saenko V, Meirmanov S, Matsumoto N, Hayashi T, Maeda S & Sekine I 2007 RET oncogene amplification in thyroid cancer: correlations with radiation-associated and highgrade malignancy. Human Pathology 38 621-628.
136. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397.
137. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 15 319-327.
138. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
139. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J, Blomgren H, Grimelius L, Lundell G & Wallin G 1998 Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World Journal of Surgery 22 725-730.
140. Nobuhara Y, Onoda N, Yamashita Y, Yamasaki M, Ogisawa K, Takashima T,
141. Onda M, Nagai H, Yoshida A, Miyamoto S, Asaka S, Akaishi J, Takatsu K, Nagahama M, Ito K, ShimizuKet et al. 2004a Up-regulation of transcriptional factor E2F1 in papillary and anaplastic thyroid cancers. Journal of Human Genetics 49 312-318.
142. Onda M, Emi M, Yoshida A, Miyamoto S, Akaishi J, Asaka S, Mizutani K, Shimizu K, Nagahama M, Ito K et al. 2004b Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocrine-Related Cancer 11 843-854.
143. Orlowski RZ & Kuhn DJ 2008 Proteasome inhibitors in cancer therapy: lessons from the first decade. Clinical Cancer Research 14 1649-1657.
144. Pacifico F, Paolillo M, Chiappetta G, Crescenzi E, Arena S, Scaloni A, Monaco M, Vascotto C, Tell G, Formisano S et al. 2007 RbAp48 is a target of nuclear factor-kappaB activity in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 92 1458-1466.
145. Pallante P, Berlingieri MT, Troncone G, Kruhoffer M, Orntoft TF, Viglietto G, Caleo A, Migliaccio I, Decaussin-Petrucci M, Santoro M et al. 2005 UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas. British Journal of Cancer 93 464-471.
146. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M et al. 2006 MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 13 497-508.
147. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V et al. 2008 Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Research 68 6770-6778.
148. Parsons JT, Slack-Davis J, Tilghman R & Roberts WG 2008 Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clinical Cancer Research 14 627-632.
149. Pierie JP, Muzikansky A, Gaz RD, Faquin WC & Ott MJ 2002 The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Annals of Surgical Oncology 9 57-64.
150. Pinkel D & Albertson DG 2005 Comparative genomic hybridization. Annual Review of Genomics and Human Genetics 6 331-354.
151. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J & Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 88 1889-1896.
152. Portella G, Scala S, Vitagliano D, Vecchio G & Fusco A 2002 ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. Journal of Clinical Endocrinology and Metabolism 87 2525-2531.
153. Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA & Mitsiades N 2002 Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. American Journal of Pathology 161 643-654.
154. Pushkarev VM, Starenki DV, Saenko VA, Namba H, Kurebayashi J, Tronko MD & Yamashita S 2004 Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology 145 3143-3152.
155. Quiros RM, Ding HG, Gattuso P, Prinz RA & Xu X 2005 Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 103 2261-2268.
156. Rao AS, Kremenevskaja N, von Wasielewski R, Jakubcakova V, Kant S, Resch J & Brabant G 2006 Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 159-168.
157. Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK & Eberhardt NL 2008 ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Therapy 15 750-757.
158. Riesco-Eizaguirre G & Santisteban P 2007 New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocrine-Related Cancer 14 957-977.
159. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC & Sobrinho-Simoes M 2003 E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology 42 580-587.
160. Rodrigues RF, Roque L, Rosa-Santos J, Cid O & Soares J 2004 Chromosomal imbalances associated with anaplastic transformation of follicular thyroid carcinomas. British Journal of Cancer 90 492-496.
161. Rodrigues RF, Roque L, Krug T & Leite V 2007 Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. British Journal of Cancer 96 1237-1245.
162. Ros P, Rossi DL, Acebron A & Santisteban P 1999 Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 81 389-396.
163. Ryder M, Ghossein R, Ricarte-Filho J, Knauf J & Fagin J 2008 Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-Related Cancer 15 1069-1074.
164. Saito Y & Jones PA 2006 Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5 2220-2222.
165. Salgia R 2008 c-Met receptor tyrosine kinase as a therapeutic target in cancer. In American Society of Clinical Oncology Educational Book, pp 113-118. Ed R Govindan. Alexandria, VA: American Society of Clinical Oncology.
166. Saltman B, Singh B, Hedvat CV, Wreesmann VB & Ghossein R 2006 Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 140 899-905 (discussion 905-896).
167. Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM et al. 2007 A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Research 67 10148-10158.
168. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/rafmitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 278-284.
169. Santoro M & Carlomagno F 2006 Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology & Metabolism 2 42-52.
170. Scala S, Portella G, Fedele M, Chiappetta G & Fusco A 2000 Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. PNAS 97 4256-4261.
171. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP & Dammann R 2002 Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Research 62 3698-3701.
172. Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C & Dammann R 2006 CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16 633-642.
173. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN et al. 2004 Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clinical Cancer Research 10 8594-8602.
174. Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP & Sarrazin D 1991 Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67 564-566.
175. Schmutzler C, Hoang-Vu C, Rüger B & Köhrle J 2004 Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. European Journal of Endocrinology 150 547-556.
176. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC et al. 2008 DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism 93 4331-4341.
177. Sebolt-Leopold JS 2008 Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clinical Cancer Research 14 3651-3656.
178. Sequeira MJ, Morgan JM, Fuhrer D, Wheeler MH, Jasani B & Ludgate M 2001 Thyroid transcription factor-2 gene expression in benign and malignant thyroid lesions. Thyroid 11 995-1001.
179. Shai RM 2006 Microarray tools for deciphering complex diseases. Frontiers in Bioscience 11 1414-1424.
180. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH & DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 2155-2160.
181. Shinohara M, Chung YJ, Saji M & Ringel MD 2007 AKT in thyroid tumorigenesis and progression. Endocrinsology 148 942-947.
182. Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M & Sobrinho-Simoes M 2004 BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv 444 572-576.
183. Sorrentino R, Libertini S, Pallante PL, Troncone G, Palombini L, Bavetsias V, Spalletti-Cernia D, Laccetti P, Linardopoulos S, Chieffi P et al. 2005 Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. Journal of Clinical Endocrinology and Metabolism 90 928-935.
184. Starenki D, Namba H, Saenko V, Ohtsuru A & Yamashita S 2004 Inhibition of nuclear factor-κB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 89 410-418.
185. Strebhardt K & Ullrich A 2006 Targeting polo-like kinase 1 for cancer therapy. Nature Reviews. Cancer 6 321-330.
186. Sultan M, Schulz MH, Richard H, Magen A, Klingenhoff A, Scherf M, Seifert M, Borodina T, Soldatov A, Parkhomchuk D et al. 2008 A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321 956-960.
187. Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch TI, Nakazawa Y, Hayashi T, Ohtsuru A & Yamashita S 2008 Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Science 99 1147-1154.
188. Takano T, Hasegawa Y, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K & Amino N 2001 Overexpression of kα1 tubulin mRNA in thyroid anaplastic carcinoma. Cancer Letters 168 51-55.
189. Takano T, Ito Y, Hirokawa M, Yoshida H & Miyauchi A 2007a BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. British Journal of Cancer 96 1549-1553.
190. Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H & Miyauchi A 2007b Quantitative measurement of telomerase reverse transcriptase, thyroglobulin and thyroid transcription factor 1 mRNAs in anaplastic thyroid carcinoma tissues and cell lines. Oncology Reports 18 715-720.
191. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S & Carcangiu ML 1999 Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. American Journal of Surgical Pathology 23 678-685.
192. Tan RK, Finley RK III, Driscoll D, Bakamjian V, Hicks WL Jr & Shedd DP 1995 Anaplastic carcinoma of the thyroid: a 24-year experience. Head & Neck 17 41-47 (discussion 47-48).
193. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL & Wallin G 2002 Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. British Journal of Cancer 86 1848-1853.
194. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A et al. 2006 Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Research 66 4263-4272.
195. Ulisse S, Delcros JG, Baldini E, Toller M, Curcio F, Giacomelli L, Prigent C, Ambesi-Impiombato FS, D'Armiento M & Arlot-Bonnemains Y 2006 Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. International Journal of Cancer 119 275-282.
196. Ulisse S, Baldini E, Toller M, Delcros JG, Gueho A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S et al. 2007 Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocrine-Related Cancer 14 827-837.
197. Veltman JA & de Vries BB 2006 Diagnostic genome profiling: unbiased whole genome or targeted analysis? Journal of Molecular Diagnostics 8 534-537 (discussion 537-539).
198. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM et al. 2007a MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocrine-Related Cancer 14 791-798.
199. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E et al. 2007b Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26 7590-7595.
200. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C & Schmoll HJ 2000 Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clinical Cancer Research 6 2087-2093.
201. Voigt W, Kegel T, Weiss M, Mueller T, Simon H & Schmoll HJ 2005 Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. Journal of Cancer Research and Clinical Oncology 131 585-590.
202. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al. 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103 2257-2261.
203. Voutilainen PE, Multanen M, Haapiainen RK, Leppaniemi AK & Sivula AH 1999 Anaplastic thyroid carcinoma survival. World Journal of Surgery 23 975-978 (discussion 978-979).
204. Vucic D 2008 Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Current Cancer Drug Targets 8 110-117.
205. Wada N, Yoshida A, Miyagi Y, Yamamoto T, Nakayama H, Suganuma N, Matsuzu K, Masudo K, Hirakawa S, Rino Y et al. 2008 Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Research 28 139-144.
206. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA & Khan A 2000 The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Modern Pathology 13 882-887.
207. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T & Brierley J 2006 Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107 1786-1792.
208. Wang Y, Hou P, Yu H, Wang W, Ji M, Zhao S, Yan S, Sun X, Liu D, Shi B et al. 2007 High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol- 3-kinase/akt pathway in thyroid tumors. Journal of Clinical Endocrinology and Metabolism 92 2387-2390.
209. Weber F, Teresi RE, Broelsch CE, Frilling A & Eng C 2006 A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 3584-3591.
210. Wilkens L, Benten D, Tchinda J, Brabant G, Potter E, Dralle H & von Wasielewski R 2000 Aberrations of chromosomes 5 and 8 as recurrent cytogenetic events in anaplastic carcinoma of the thyroid as detected by fluorescence in situ hybridisation and comparative genomic hybridisation. Virchows Archiv 436 312-318.
211. Williams SF & Smallridge RC 2004 Targeting the ERK pathway: novel therapeutics for thyroid cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders 4 199-220.
212. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Filipenko D, Huntsman D & Gilks B 2006 Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. American Journal of Surgery 191 581-587.
213. Wiseman SM, Griffith OL, Deen S, Rajput A, Masoudi H, Gilks B, Goldstein L, Gown A & Jones SJ 2007a Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Archives of Surgery 142 717-727 (discussion 727-729).
214. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, Bugis S, Filipenko D, Huntsman D & Gilks B 2007b Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Annals of Surgical Oncology 14 719-729.
215. Wreesmann VB & Singh B 2008 Clinical impact of molecular analysis on thyroid cancer management. Surgical Oncology Clinics of North America 17 1-35 (vii).
216. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH & Singh B 2002 Genome-wide appraisal of thyroid cancer progression. American Journal of Pathology 161 1549-1556.
217. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M et al. 2004 Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Research 64 3780-3789.
218. Xing M 2007 Gene methylation in thyroid tumorigenesis. Endocrinology 148 948-953.
219. Xu G, Pan J, Martin C & Yeung SC 2001 Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 1769-1777.
220. Xu J, Filetti S & Hershman JM 2008 Expression of hepatocyte nuclear factor-1α mRNA in human anaplastic thyroid cancer cell lines and tumors. Thyroid 18 533-539.
221. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB et al. 2005 Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Molecular Cancer Therapeutics 4 1146-1156.
222. Yu W, Imoto I, Inoue J, Onda M, Emi M & Inazawa J 2007 A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26 1178-1187.
223. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen AL & Auer G 1996 Alterations of p53 and expression of WAF1/ p21 in human thyroid tumors. Thyroid 6 1-9.
224. Zhang L & Coukos G 2006 MicroRNAs: a new insight into cancer genome. Cell Cycle 5 2216-2219.
225. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T & Kakudo K 2006 Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. Pathology International 56 240-245.
226. Zhang H-Y, Wang H-Q, Liu H-M, Guan Y & Du Z-X 2008 Regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by DJ-1 in thyroid cancer cells. Endocrine-Related Cancer 15 535-544.
227. Zou M, Shi Y & Farid NR 1993 p53 mutations in all stages of thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 77 1054-1058.